PURPOSE: DNA mismatch repair (MMR) maintains genomic stability and mediates cellular response to DNA damage. We aim to demonstrate whether MMR genetic variants affect overall survival (OS) in pancreatic cancer. MATERIALS AND METHODS: Using the Sequenom method in genomic DNA, we retrospectively genotyped 102 single-nucleotide polymorphisms (SNPs) of 13 MMR genes from 706 patients with pancreatic adenocarcinoma seen at The University of Texas MD Anderson Cancer Center. Association between genotype and OS was evaluated using multivariable Cox proportional hazard regression models. RESULTS: At a false discovery rate of 1% (p ≤ .0015), 15 SNPs of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, TP73, and TREX1 in patients with localized disease (n = 333) and 6 SNPs of MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease (n = 373) were significantly associated with OS. In multivariable Cox proportional hazard regression models, SNPs of EXO1, MSH2, MSH3, PMS2L3, and TP73 in patients with localized disease, MSH2, MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease, and EXO1, MGMT, MSH2, MSH3, MSH6, PMS2L3, and TP73 in all patients remained significant predictors for OS (p ≤ .0015) after adjusting for all clinical predictors and all SNPs with p ≤ .0015 in single-locus analysis. Sixteen haplotypes of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, RECQL, TP73, and TREX1 significantly correlated with OS in all patients (p ≤ .001). CONCLUSION: MMR gene variants may have potential value as prognostic markers for OS in pancreatic cancer patients.
PURPOSE: DNA mismatch repair (MMR) maintains genomic stability and mediates cellular response to DNA damage. We aim to demonstrate whether MMR genetic variants affect overall survival (OS) in pancreatic cancer. MATERIALS AND METHODS: Using the Sequenom method in genomic DNA, we retrospectively genotyped 102 single-nucleotide polymorphisms (SNPs) of 13 MMR genes from 706 patients with pancreatic adenocarcinoma seen at The University of Texas MD Anderson Cancer Center. Association between genotype and OS was evaluated using multivariable Cox proportional hazard regression models. RESULTS: At a false discovery rate of 1% (p ≤ .0015), 15 SNPs of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, TP73, and TREX1 in patients with localized disease (n = 333) and 6 SNPs of MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease (n = 373) were significantly associated with OS. In multivariable Cox proportional hazard regression models, SNPs of EXO1, MSH2, MSH3, PMS2L3, and TP73 in patients with localized disease, MSH2, MSH3, MSH6, and TP73 in patients with locally advanced or metastatic disease, and EXO1, MGMT, MSH2, MSH3, MSH6, PMS2L3, and TP73 in all patients remained significant predictors for OS (p ≤ .0015) after adjusting for all clinical predictors and all SNPs with p ≤ .0015 in single-locus analysis. Sixteen haplotypes of EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, RECQL, TP73, and TREX1 significantly correlated with OS in all patients (p ≤ .001). CONCLUSION: MMR gene variants may have potential value as prognostic markers for OS in pancreatic cancerpatients.
Authors: Rakesh R Khakhar; Jennifer A Cobb; Lotte Bjergbaek; Ian D Hickson; Susan M Gasser Journal: Trends Cell Biol Date: 2003-09 Impact factor: 20.808
Authors: Santhi D Konduri; Jonathan Ticku; George C Bobustuc; Robert M Sutphin; Jimmie Colon; Beth Isley; Kishor K Bhakat; Kalkunte S Srivenugopal; Srivenugopal S Kalkunte; Cheryl H Baker Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Paolo Lunghi; Antonio Costanzo; Laura Mazzera; Vittorio Rizzoli; Massimo Levrero; Antonio Bonati Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: Jens Plaschke; Stefan Krüger; Birgit Jeske; Franz Theissig; Friedmar R Kreuz; Steffen Pistorius; Hans D Saeger; Ingram Iaccarino; Giancarlo Marra; Hans K Schackert Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein Journal: Clin Cancer Res Date: 2012-06-04 Impact factor: 12.531
Authors: Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil Journal: Ann Surg Date: 2014-02 Impact factor: 12.969
Authors: Maziar Riazy; Steve E Kalloger; Brandon S Sheffield; Renata D Peixoto; Hector H Li-Chang; Charles H Scudamore; Daniel J Renouf; David F Schaeffer Journal: Mod Pathol Date: 2015-07-31 Impact factor: 7.842